Radiation therapy plus anti-programmed death ligand 1 immunotherapy: A review on overall survival

Radiologic Technology

Volumn 88, Issue 1, 2016, Pages 123-128

  Krcik, Elizabeth Marie ^a  

^a Northwestern University Feinberg School of Medicine   (United States)

Author keywords

Anti PD L1 therapy; Metastatic melanoma; Metastatic non small cell lung cancer; Nivolumab; Preclinical studies; Radiation therapy

Indexed keywords

ATEZOLIZUMAB; MONOCLONAL ANTIBODY;

ANIMAL; CHEMORADIOTHERAPY; HUMAN; IMMUNOLOGY; META ANALYSIS; MORTALITY; MOUSE; NEOPLASMS; PREVALENCE; SPECIES DIFFERENCE; SURVIVAL RATE; TREATMENT OUTCOME; UTILIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; CHEMORADIOTHERAPY; HUMANS; MICE; NEOPLASMS; PREVALENCE; SPECIES SPECIFICITY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84992524535     PISSN: 00338397     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (12)

1. Hekim N, Cetin Z, Nikitaki Z, Cort A, Saygili EI. Radiation triggering immune response and inflammation. Cancer Lett. 2015;368(2):156-163. doi:10.1016/j.canlet.2015.04.016.
2. Zeng J, Harris TJ, Lim M, Drake CG, Tran PT. Immune modulation and stereotactic radiation: improving local and abscopal responses. Biomed Res Int. 2013;2013:658126. doi:10.1155/2013/658126.
3. Deng L, Liang H, Burnette B, Weichselbaum RR, Fu YX. Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression. Oncoimmunology. 2014;3(4):e28499. doi:10.4161/onci.28499.
4. Nivolumab. National Cancer Institute Web site. http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid =539733. Accessed February 3, 2016.
5. Deng L, Liang H, Burnette B, et al. Irradiation and anti-PDL1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124(2):687-695. doi:10.1172/JCI67313.
6. Gandhi SJ, Minn AJ, Vonderheide RH, Wherry EJ, Hahn SM, Maity A. Awakening the immune system with radiation: optimal dose and fractionation. Cancer Lett. 2015;368(2):185-190 doi:10.1016/j.canlet.2015.03.024.
7. Seyedin SN, Schoenals JE, Lee DA, et al. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy. 2015;7(9):967-968. doi:10.2217/imt.15.65.
8. Smith CA, Freeman ML. Preclinical advances in combinedmodality cancer immunotherapy with radiation therapy. Int J Radiat Oncol Biol Phys. 2016;94(1):11-14. doi:10.1016/j.ijrobp.2015.07.2282.
9. Crittenden M, Kohrt H, Levy R, et al. Current clinical trials testing combinations of immunotherapy and radiation. Semin Radiat Oncol. 2015;25(1):54-61. doi:10.1016/j.semra donc.2014.07.003.
10. Chen L, Douglass J, Walker AJ, et al. Concurrent immunotherapy and stereotactic radiosurgery for brain metastases is associated with a decreased incidence of new intracranial metastases. Int J Radiat Oncol Biol Phys. 2015;93(3):E102. doi:10.1016/j.ijrobp.2015.07.807.
11. Ahmed KA, Stallworth DG, Kim Y, et al. Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Ann Oncol. 2016;27(3):434-441. doi:10.1093/annonc/mdv622.
12. Opdivo (nivolumab). Bristol-Myers-Squibb Web site. http://www.opdivo.bmscustomerconnect.com. Accessed June 10, 2016.